ClinicalTrials.gg
Not yet recruitingNCT07944651Updated Nov 18, 2026

Pirtobrutinib With Sonrotoclax and Rituximab for High-Risk Relapsed/Refractory Mantle-Cell Lymphoma Following Covalent BTK-Inhibitor Failure

A Phase 2 interventional study of Pirtobrutinib and Sonrotoclax in Mantle Cell Lymphoma (MCL) and Relapsed/Refractory Mantle Cell Lymphoma (MCL), sponsored by Tianjin Medical University Cancer Institute and Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Tianjin Medical University Cancer Institute and Hospital · Phase 2, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 13 studies testing pirtobrutinib in Lymphoma, Mantle-Cell — 9 open to participants now, 11 under way, 1 of them phase 3. pirtobrutinib · Lymphoma, Mantle-Cell.

Planned enrollment
10th of 13
35 · median 50
Started
2026
with 1 other
Phase 2
10 of 13
8 open now
Primary completion
2028-12
later than 7 of 10 live
Registered
13th of 13
by date
Lead sponsor
1 of 13
Tianjin Medical University Cancer Institute and Hospital

Among the 13 studies testing pirtobrutinib in Lymphoma, Mantle-Cell, this one is the 10th largest by planned enrollment, is one of 2 that started in 2026, is one of 10 in phase 2, reaches primary completion later than 7 of the 10 other live ones, and was the 13th registered.

Lymphoma, Mantle-Cell

1,223 studies on the registry are indexed under Lymphoma, Mantle-Cell; 156 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

9 of the 13 studies testing pirtobrutinib in Lymphoma, Mantle-Cell are open now, in 6 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About pirtobrutinib

pirtobrutinib: first FDA approval 2023 (JAYPIRCA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 93 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing pirtobrutinib in Lymphoma, Mantle-Cell, or all of them as a file.
02

Study summary

This single-arm, multicenter, open-label phase II study aims to evaluate the efficacy and safety of pirtobrutinib plus sonrotoclax and rituximab in adults with high-risk relapsed/refractory mantle cell lymphoma after failure of prior covalent BTK-inhibitor therapy. **Approximately 35 patients are planned to be enrolled**. Subjects will receive 28-day cycles of the triple-drug regimen. Participants achieving complete response with undetectable MRD at cycle 12 may stop treatment; others may continue up to 24 cycles. The primary endpoint is the CR-uMRD rate at cycle 12. Secondary endpoints include ORR, CRR, DOR, PFS, OS and safety. Exploratory biomarker and quality-of-life analyses will also be performed.

Read the detailed description

This is a prospective single-arm, multicenter, open-label phase II trial. **Approximately 35 adult patients with histologically-confirmed high-risk relapsed/refractory mantle cell lymphoma who progressed after covalent BTK-inhibitor-containing therapy are planned to be enrolled**. Eligible patients will receive pirtobrutinib 200 mg once-daily, sonrotoclax ramp-up to 320 mg once-daily, and rituximab 375 mg/m² on day 1 of each 28-day cycle. Patients with CR-uMRD after 12 cycles may discontinue study treatment; remaining patients can continue therapy for a maximum of 24 cycles. Tumor response, MRD and safety (CTCAE 5.0) will be assessed regularly. All patients will receive long-term survival follow-up after treatment. Biomarker and patient-reported quality-of-life assessments will be conducted as exploratory analyses.

03

Conditions studied

  • Mantle Cell Lymphoma (MCL)
  • Relapsed/Refractory Mantle Cell Lymphoma (MCL)

Keywords

  • Mantle cell lymphoma
  • Pirtobrutinib
  • Sonrotoclax
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.Histopathologically-confirmed mantle cell lymphoma (MCL) with documented t(11;14)(q13;q32) translocation and/or cyclin-D1 over-expression, accompanied by relevant biomarkers (e.g., CD5, CD19, CD20, or PAX5). All subjects must provide sufficient archived or fresh tumor tissue samples for immunohistochemistry (IHC) testing.
  • 2.Age ≥ 18 years, male or female.
  • 3. Received at least one containing a covalent BTK-inhibitor.
  • 4.Histopathologically-confirmed high-risk MCL, defined as meeting at least one of the following criteria: POD24, complex karyotype, TP53 mutation, del(17p), high-risk MIPI score, blastoid / pleomorphic variant, Ki-67 ≥ 30 %, bulky disease.
  • 5.Presence of at least one . Measurable disease is defined as a tumor mass ≥ 1.5 cm in one or two dimensions; splenic lesions are considered measurable.
  • 6. (ECOG) performance status of 0-2.
  • 7.Adequate hematological function:

    1. (ANC) ≥ 1 × 10⁹/L without growth-factor support within 7 days prior to testing;
    2. count ≥ 75 × 10⁹/L, or ≥ 50 × 10⁹/L in the setting of bone-marrow involvement; no growth-factor support or transfusion within 7 days prior to testing.
  • 8.Adequate hepatic function:

    1. (AST) and alanine aminotransferase (ALT) ≤ 2.5 × (ULN);
    2. Total ≤ 2 × ULN, except for subjects with confirmed Gilbert syndrome, in whom bilirubin up to 5 × ULN is permitted.
  • 9.Adequate renal function:

    1. ≥ 60 mL/min (estimated by the Cockcroft-Gault formula, or calculated using the Modification of Diet in Renal Disease [MDRD] formula);
    2. Serum creatinine ≤ 1.5 × ULN.
  • 10. (INR) ≤ 1.5 × ULN and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.
  • 11.For females of , two negative pregnancy tests (at least one serum pregnancy test) are required prior to treatment initiation. The first test must be performed 10-14 days before the first dose of sonrotoclax; the second test must be performed within 24 hours before the first dose of sonrotoclax.
  • 12.Females of child-bearing potential must agree to use two reliable methods (one highly-effective method plus one additional effective method), starting 4 weeks prior to initiating sonrotoclax, throughout study participation, and for at least 90 days after the last dose of pirtobrutinib or 12 months after the last dose of rituximab (whichever is longer). Highly-effective contraception includes abstinence, hysterectomy, bilateral oophorectomy with 6-month amenorrhea, intrauterine system, and hormonal contraception (e.g., injectable or oral contraceptives). Male subjects must be vasectomized or use barrier contraception while their female partners employ effective contraception as described above. Male subjects must refrain from sperm donation during the study and for at least 90 days after the last dose of pirtobrutinib and sonrotoclax, or for 12 months after the last dose of rituximab (whichever is longer).
  • 13.Estimated > 3 months.
  • 14.Capable of providing written , and able to understand and comply with study requirements.

Exclusion criteria

Exclusion Criteria:

  • 1. Current or suspected central nervous system (CNS) involvement of mantle cell lymphoma, or a prior history of CNS-involved disease.
  • 2. Prior treatment with a BCL-2 inhibitor or pirtobrutinib.
  • 3. Major surgery within 4 weeks prior to screening. Note: If a subject has undergone major surgery, they must have fully recovered from any toxicities and/or complications of the intervention before receiving the first dose of study drug.
  • 4. History of other active malignant disease within 2 years before entering the study, with the following exceptions: (1) adequately-treated carcinoma in-situ of the cervix; (2) localized basal-cell or squamous-cell skin carcinoma; (3) previously-diagnosed that has been controlled with curative-intent local treatment (surgery or other modalities).
  • 5. Active, uncontrolled systemic fungal, bacterial, or viral infection (defined as persistent signs/symptoms related to infection with no improvement despite appropriate antibiotic, antiviral, and/or other therapy).
  • 6. Known (HIV) infection, or serology suggestive of active or infection, as follows:

    1. Subjects who are hepatitis B core antibody (HBcAb)-positive and hepatitis B surface antigen (HBsAg)-negative must have a negative HBV-PCR result prior to the first study-drug dose. Subjects who are HBsAg-positive or HBV-DNA-positive are excluded.
    2. Subjects with positive hepatitis C antibody must have a negative HCV-RNA result before the first dose of study drug. Subjects with positive HCV-PCR are excluded.
  • 7. cardiovascular disease, including:

    1. Myocardial infarction within 6 months before screening;
    2. Unstable angina within 3 months before screening;
    3. Clinically significant arrhythmias (e.g., sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes);
    4. (Fridericia correction) > 480 msec;
    5. History of second-degree type-II or third-degree atrioventricular (AV) block;
    6. (NYHA) class III or IV congestive heart failure.
  • 8. History of severe bleeding disorders, such as hemophilia A, hemophilia B, von Willebrand disease, or history of spontaneous bleeding requiring transfusion or other medical intervention.
  • 9. History of deep-vein thrombosis (DVT) or pulmonary embolism (PE) within the previous 12 months.
  • 10. History of a major cerebrovascular event (including stroke or intracranial hemorrhage) within 6 months before the first dose of study drug.
  • 11. Requiring ongoing treatment with strong or moderate inhibitors or CYP3A inducers. Subjects who have received strong/moderate CYP3A inhibitors or inducers within 7 days (or less than 5 drug half-lives) before the first study-drug dose are excluded. Subjects receiving moderate CYP3A inhibitors may be considered for enrollment after a minimum 7-day .
  • 12. Requiring anticoagulation with warfarin or an equivalent vitamin-K antagonist (e.g., phenprocoumon) within 7 days of the first study-drug dose.
  • 13. Active bleeding gastrointestinal ulcer, except cases attributable to mantle-cell lymphoma identified on endoscopy.
  • 14. Known to urate-lowering agents.
  • 15. History of toxic epidermal necrolysis or Stevens-Johnson syndrome.
  • 16. Pregnant or breastfeeding women.
  • 17. Known hypersensitivity to any of the study drugs.
  • 18. Any psychiatric or cognitive disorder that may limit the subject's ability to understand, provide , or comply with study requirements.
  • 19. Subjects with active drug or alcohol abuse. Any life-threatening disease, medical condition, or organ-system dysfunction that, in the investigator's judgment, may jeopardize subject safety or introduce additional risks to participation in the study.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    Pirtobrutinib + Sonrotoclax + Rituximab Combination Therapy

    Patients receive pirtobrutinib 200 mg once daily continuously, sonrotoclax dose-escalated to 320 mg once daily, plus rituximab 375 mg/m² on Day 1 of each 28-day cycle. Treatment may stop at Cycle 12 for patients achieving CR-uMRD, with a maximum treatment duration of 24 cycles.

    Drug: Pirtobrutinib · Drug: Sonrotoclax · Drug: Rituximab injection

Interventions

  • 200 mg oral once daily, continuous administration throughout the treatment cycle (28-day cycle)

  • Dose ramp-up within the first 4 weeks to the target dose of 320 mg oral once daily, continuous dosing.

  • 375 mg/m² intravenous infusion administered on Day 1 of each 28-day treatment cycle.

06

What researchers measure

Primary outcomes

  1. Rate of complete response with undetectable minimal residual disease (CR-uMRD) at Cycle 12

    Proportion of patients with high-risk relapsed/refractory mantle cell lymphoma who achieve complete response (CR) with undetectable minimal residual disease (uMRD) after 12 cycles of pirtobrutinib, sonrotoclax, and rituximab combination therapy. uMRD is defined as peripheral blood MRD \<10-⁵ as measured by the clonoSEQ assay.

    Time frame: At the end of Cycle 12 (each cycle is 28 days)

Secondary outcomes

  1. Overall Response Rate (ORR) at Cycle 12

    Proportion of patients achieving complete response (CR) or partial response (PR) after 12 cycles of pirtobrutinib, sonrotoclax, and rituximab combination therapy, assessed per standard lymphoma response criteria.

    Time frame: At the end of Cycle 12 (each cycle is 28 days)

  2. Complete Response Rate (CRR) at Cycle 12

    Proportion of patients achieving complete response (CR) after 12 cycles of pirtobrutinib, sonrotoclax, and rituximab combination therapy, assessed per standard lymphoma response criteria.

    Time frame: At the end of Cycle 12 (each cycle is 28 days)

  3. Duration of Response(DOR)

    The length of time between the achievement of criteria for response to treatment (first documented complete or partial response) and the first documented relapse or progression.

    Time frame: From initial objective response until progression, death, or the end of study follow-up, maximum 36-months after treatment initiation

  4. Progression-free survival (PFS)

    The time from the enrollment of a subject to the occurrence of (in any way) progression of disease or Death for any reason. patients with indeterminate recurrence or Death at the last follow-up, defined as the date of the last Investigation

    Time frame: From first drug dose until progression, death, or end of study follow-up, maximum 36-months after treatment initiation

  5. Overall Survival (OS)

    Time from the first dose of study treatment to death from any cause. Patients still alive will be censored at the date last known to be alive or the end-of-study follow-up.

    Time frame: From first drug dose until death or end of study follow-up, maximum 36-months after treatment initiation

  6. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Adverse events (AEs) and serious adverse events (SAEs) will be monitored throughout the study based on physical examination findings and laboratory test results, and graded according to NCI-CTCAE Version 5.0.

    Time frame: From the first dose of study treatment until 30 days after the last dose of study treatment

  7. MRD Conversion and Subsequent MRD Relapse Rate

    Rate of MRD negativity and subsequent MRD relapse assessed by high-sensitivity flow cytometry.Rate of conversion to MRD negativity and subsequent MRD relapse, assessed by high-sensitivity flow cytometry.

    Time frame: At the end of Cycle 12 (each cycle is 28 days), at the end of Cycle 24 (each cycle is 28 days)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.

Of 154 non-industry phase 2 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 108. This study's planned 24 months is below that.

Counting every sponsor, half of 184 studies reached it within 63 months; a quarter within 38 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2026
First posted
Nov 18, 2026
StartEst.
Dec 8, 2026
Primary completionEst.
Dec 8, 2028
CompletionEst.
Dec 8, 2030
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07944651
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Dec 8, 2026 (estimated)
Primary completion
Dec 8, 2028 (estimated)
Completion
Dec 8, 2030 (estimated)
Last update
Nov 18, 2026

Study contacts

Huilai Zhang
Contact
huilaizhangtz@163.com
+86-18622221228

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pirtobrutinib · Sonrotoclax · Rituximab

Start the discussion